Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Gwenola,Manic ^[1] ; Florine,Obrist ^[2] ; Antonella,Sistigu ^[1] ; Ilio,Vitale ^[3]

作者单位： Regina Elena National Cancer Institute ; Rome, Italy. ^[1] Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre, France; INSERM, UMRS1138; Paris, France; Equipe 11 labelisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers; Paris, France; Gustave Roussy Cancer Campus; Villejuif, France. ^[2] Regina Elena National Cancer Institute; Rome, Italy; Department of Biology, University of Rome "TorVergata"; Rome, Italy. ^[3]

关键词 DNA lesions UCN-01 cell cycle checkpoint cell death double-strand breaks drug resistance genomic instability

DOI 10.1080/23723556.2015.1012976

PMID 27308506

发布时间 2024-05-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览11

Molecular & cellular oncology

e1012976页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Molecular & cellular oncology

相似文献

Molecular & cellular oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Molecular & cellular oncology

相似文献

Molecular & cellular oncology

相关期刊

检索历史清除